ClearPoint Neuro (CLPT) said late Wednesday the US Food and Drug Administration has granted de novo marketing authorization for its SmartFlow Neuro Cannula for the delivery of PTC Therapeutics' (PTCT) Kebilidi gene therapy to targeted regions within the brain.
Kebilidi is indicated for the treatment of aromatic L-amino acid decarboxylase deficiency, a genetic disorder that typically results in disability, the company said.
Price: 12.00, Change: +1.05, Percent Change: +9.59
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.